Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634357 · ClinicalTrials.gov registry record · Phase 1
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
A Phase 1 study of Liver Cancer and Hepatocellular Carcinoma (HCC), sponsored by Eureka Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT04634357 is a Phase 1 study of Liver Cancer and Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by Eureka Therapeutics. The registered enrollment target is 15 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04634357, a Phase 1 study of Liver Cancer and Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by Eureka Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
Conditions Studied
Interventions
- DRUG ET140203 T Cells
Study Locations (2)
California
- UCSF Benioff Children's Hospitals - San Francisco
Massachusetts
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-07-19 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634357
The ClinicalTrials.gov registry entry for NCT04634357 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Eureka Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which ET140203 T Cells is the first listed.
NCT04634357 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04634357 about?
NCT04634357 is a clinical study titled "ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma". Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
What is the current status of trial NCT04634357?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-07-19. Estimated completion is 2028-01-31.
What conditions does trial NCT04634357 study?
This clinical trial studies the following conditions: Liver Cancer, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Hepatoblastoma, Metastatic Liver Cancer.
What interventions are being tested in trial NCT04634357?
The interventions under investigation include: ET140203 T Cells (DRUG).
Who is sponsoring clinical trial NCT04634357?
This trial is sponsored by Eureka Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04634357 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RECRUITING · Phase 1
-
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
ACTIVE NOT RECRUITING · Phase 1
-
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.